研究等業績 - その他 - 有田　淳一

The afsumb consensus statements and recommendations for the clinical practice of contrast-enhanced ultrasound using sonazoid

Lee J.Y.

Ultrasonography ( Ultrasonography )  39 ( 3 ) 191 - 220   2020年

DOI

Intestinal-type histology is associated with better prognosis in patients undergoing liver resection for gastric/esophagogastric-junction liver metastasis

Ito Daisuke, Kawaguchi Yoshikuni, Yamashita Hiroharu, Arita Junichi, Akamatsu Nobuhisa, Kaneko Junichi, Sakamoto Yoshihiro, Kokudo Norihiro, Seto Yasuyuki, Hasegawa Kiyoshi

Global Health & Medicine ( 国立研究開発法人 国立国際医療研究センター )  1 ( 2 ) 101 - 109   2019年12月

<p>The indication for resection of gastric/esophagogastric-junction liver metastasis (GELM) has yet to be established. This study aimed to investigate prognostic factors in patients undergoing GELM resection. From 2001 to 2015, 31 consecutive patients underwent resection for GELM; and factors for poor prognosis were evaluated. Of the 31 patients, 23 (74.2%) developed multiple liver metastases. The histology of gastric cancer was intestinal-type adenocarcinoma in 21 patients (67.7%). Median overall survival (OS) was 3.2 years. The 1-, 3-, and 5-year OS rates were 92.8%, 56.2%, and 42.2%, respectively. The 1-, 3-, and 5-year recurrence-free survival (RFS) rates were 58.5%, 31.3%, and 31.3%, respectively. Multivariate analysis indicated that intestinal-type adenocarcinoma was associated with a significantly lower risk of OS (hazard ratio [HR], 0.26; <i>p</i> =0.022) and RFS (HR, 0.25; <i>p</i> = 0.008). In multiple logistic regression analysis, intestinal-type adenocarcinoma (odds ratio, 0.14; <i>p</i> = 0.012) reduced incidence of extra-hepatic recurrence after GELM resection. In conclusion, GELM resection in patients with intestinal-type histology is preferable because intestinal-type adenocarcinoma is associated with better prognosis and a lower incidence of extra-hepatic recurrence than diffuse/other-type adenocarcinoma.</p>

DOI PubMed CiNii Research

Significance of Glisson's capsule invasion in patients with colorectal liver metastases undergoing resection

Hiroyoshi J.

American Journal of Surgery ( American Journal of Surgery )  218 ( 5 ) 887 - 893   2019年11月

DOI

増刊号 すぐに使える周術期管理マニュアル Ⅲ章　術式別の術前・術中・術後管理 肝 化学療法後の肝切除

増田 晃一, 有田 淳一, 長谷川 潔

臨床外科 ( 株式会社医学書院 )  74 ( 11 ) 163 - 166   2019年10月

DOI CiNii Research

Albumin–Indocyanine Green Evaluation (ALICE) grade combined with portal hypertension to predict post-hepatectomy liver failure

Shirata C.

Hepatology Research ( Hepatology Research )  49 ( 8 ) 942 - 949   2019年08月

DOI

特集 肝胆膵外科手術におけるトラブルシューティング Ⅱ.胆道　2)肝門部領域胆管癌手術における細径・菲薄胆管の再建法

松村 優, 有田 淳一, 石沢 武彰, 金子 順一, 赤松 延久, 長谷川 潔

手術 ( 金原出版 )  73 ( 7 ) 1035 - 1042   2019年06月

DOI CiNii Research

特集 肝胆膵外科の臨床研究 update 2019 5.肝切除周術期管理に関するRCT

有田 淳一, 石沢 武彰, 金子 順一, 赤松 延久, 長谷川 潔

外科 ( 南江堂 )  81 ( 6 ) 636 - 643   2019年05月

DOI CiNii Research

特集 高度進行消化器癌に対する手術 Ⅲ　肝・胆・膵　3　Partial TIPE ALPPSによる二期的肝切除

宮田 明典, 有田 淳一, 赤松 延久, 稲垣 冬樹, 阪本 良弘, 長谷川 潔

手術 ( 金原出版 )  73 ( 4 ) 523 - 529   2019年03月

DOI CiNii Research

EVI1 expression is associated with aggressive behavior in intrahepatic cholangiocarcinoma

Tanaka M.

Virchows Archiv ( Virchows Archiv )  474 ( 1 ) 39 - 46   2019年01月

DOI

A selective oral vasopressin V2-receptor antagonist for patients with end-stage liver disease awaiting liver transplantation: A preliminary study

Kiritani S.

BioScience Trends ( BioScience Trends )  13 ( 2 ) 189 - 196   2019年

<p>Administration of the selective arginine vasopressin V2 receptor antagonist tolvaptan to cirrhotic patients is controversial. There are no reports of tolvaptan use for patients with far-advanced end-stage liver disease (ESLD) and refractory ascites awaiting liver transplantation. Between 2013 and 2016, 64 patients awaiting adult-to-adult living donor liver transplantation (LDLT) were screened for enrollment. Patients with refractory ascites and on dual conventional diuretics (≥ 50 mg/day of spironolactone and ≥ 20 mg/day of a loop diuretic) were enrolled and assigned to the tolvaptan (TOL) group (<i>n</i> = 10), and low-dose tolvaptan, 3.75 mg/day, was started. The remaining patients who had no or little ascites on conventional diuretic therapy (CDT) were assigned to the CDT group (<i>n</i> = 23). The median model for end-stage liver disease and Child-Pugh scores were 16 (range 7-41) and 10 (7-15), respectively. The median dose of spironolactone in the TOL group was 88 mg (range 50-200) <i>vs</i>. 50 (0-100) in the CDT group (<i>p</i> < 0.01). The median dose of loop diuretics in the TOL group was 70 mg (20-120) <i>vs</i>. 20 (0-80) in the CDT group (<i>p</i> = 0.03). No significant liver damage was detected during tolvaptan therapy. Tolvaptan demonstrated favorable effects in 60% (6/10) of the patients, decreasing the body weight by at least 1.5 kg during the 7 day treatment. These findings suggest that low-dose of tolvaptan may be safe for patients having far-advanced ESLD patients with apparent and refractory ascites taking dual conventional diuretics for a short period before LDLT.</p>

DOI PubMed CiNii Research

Hepatitis B virus recurrence after living donor liver transplantation of anti-HBc-positive grafts: A 22-year experience at a single center

Bae S.K.

BioScience Trends ( BioScience Trends )  13 ( 5 ) 448 - 455   2019年

<p>The use of hepatitis B core antibody (anti-HBc)-positive grafts is one strategy for expanding the donor pool for liver transplantation (LT). The aim of this study was to determine the risk factors associated with hepatitis B virus (HBV) recurrence after living donor LT (LDLT) of anti-HBc-positive grafts. From January 1996 to December 2018, a total of 609 LDLT procedures were performed at our center. A retrospective review was performed for 31 patients (23 males and 8 females; median age = 47 years) who underwent LDLT for HBV-unrelated liver disease from anti-HBc-positive donors. The factors associated with HBV recurrence were evaluated and compared between the HBV recurrence and non-recurrence groups. The median follow-up period after LT was 135 months (range, 6-273 months). Four of 31 patients (12.9%) developed post-LT HBV recurrence. All four cases were HBV-naïve patients (anti-HBc-negative and Hepatitis B surface antibody-negative). The median interval between LDLT and HBV recurrence was 42 months (range, 20-51). The overall actuarial rates of HBV recurrence at 1, 3, 5, 10, and 20 years were 0%, 7.2%, 15.7%, 15.7%, and 15.7%, respectively. Although there were no significant differences between the HBV recurrence and non-recurrence groups, HBV recurrence tended to occur in HBV-naïve recipients (<i>P</i> = 0.093). HBV-naïve status may contribute to HBV recurrence after LDLT for HBV-unrelated liver disease from anti-HBc-positive donors. Careful monitoring for serological HBV markers is needed, particularly in this group.</p>

DOI PubMed CiNii Research

Liver Regeneration is Preserved After At Least Four Repeated Liver Resections for Hepatocellular Carcinoma

Yamaguchi T.

World Journal of Surgery ( World Journal of Surgery )  42 ( 12 ) 4070 - 4080   2018年12月

DOI

Liver Resection for Hepatocellular Carcinoma in Patients with Renal Dysfunction

Shirata C.

World Journal of Surgery ( World Journal of Surgery )  42 ( 12 ) 4054 - 4062   2018年12月

DOI

Usefulness of indocyanine green-fluorescence imaging for real-time visualization of pancreas neuroendocrine tumor and cystic neoplasm

Shirata C.

Journal of Surgical Oncology ( Journal of Surgical Oncology )  118 ( 6 ) 1012 - 1020   2018年11月

DOI

増刊号 あたらしい外科局所解剖全図-ランドマークとその出し方 肝胆膵 膵頭十二指腸切除に必要な局所解剖-replaced right hepatic arteryへの対応法

風見 由祐, 阪本 良弘, 赤松 延久, 有田 淳一, 金子 順一, 長谷川 潔

臨床外科 ( 株式会社医学書院 )  73 ( 11 ) 238 - 243   2018年10月

DOI CiNii Research

Anatomical Boundary Between the Caudate Lobe of the Liver and Adjacent Segments Based on Three-Dimensional Analysis for Precise Resections

Maki H.

Journal of Gastrointestinal Surgery ( Journal of Gastrointestinal Surgery )  22 ( 10 ) 1709 - 1714   2018年10月

DOI

Contrast-enhanced intraoperative ultrasound in the resection of colorectal liver metastases with intrabiliary growth

Hiroyoshi J.

Clinical Journal of Gastroenterology ( Clinical Journal of Gastroenterology )  11 ( 5 ) 348 - 353   2018年10月

DOI

Multi-center clinical evaluation of streptozocin-based chemotherapy for advanced pancreatic neuroendocrine tumors in Japan: focus on weekly regimens and monotherapy

Shibuya H.

Cancer Chemotherapy and Pharmacology ( Cancer Chemotherapy and Pharmacology )  82 ( 4 ) 661 - 668   2018年10月

DOI

Parenchyma-sparing liver resection for hepatocellular carcinoma in left lateral section is associated with better liver volume recovery

Kobayashi K.

HPB ( HPB )  20 ( 10 ) 949 - 955   2018年10月

DOI

特集 胆管癌の手術 肝門部領域胆管癌に対する左三区域切除

松村 優, 有田 淳一, 赤松 延久, 金子 順一, 石沢 武彰, 長谷川 潔

手術 ( 金原出版 )  72 ( 10 ) 1481 - 1489   2018年09月

DOI CiNii Research